Adam Dubow Sells 6,395 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Adam Dubow sold 6,395 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider owned 72,694 shares of the company’s stock, valued at approximately $843,250.40. This represents a 8.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $12.07 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $13.20. The company has a market cap of $1.24 billion, a P/E ratio of -7.94 and a beta of -1.26. The stock’s fifty day moving average price is $10.42 and its 200-day moving average price is $8.59.

Wall Street Analysts Forecast Growth

DAWN has been the subject of a number of recent research reports. TD Cowen started coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target for the company. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. Piper Sandler upped their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in Day One Biopharmaceuticals by 40.4% during the first quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock valued at $1,474,000 after purchasing an additional 53,459 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Day One Biopharmaceuticals by 601.4% during the 1st quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock valued at $4,906,000 after purchasing an additional 530,429 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Day One Biopharmaceuticals by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock valued at $302,000 after purchasing an additional 2,149 shares during the period. Millennium Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 587.2% during the 1st quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock valued at $10,468,000 after buying an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock worth $12,449,000 after buying an additional 1,097,679 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.